Meglumine antimonate
From Wikidoc - Reading time: 3 min
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| NIAID ChemDB | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | Variable |
| Molar mass | Variable |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
[edit | edit source]Meglumine antimoniate (or meglumine antimonate) is a medicine used for treating leishmaniasis.[1] It is manufactured by Aventis[2] and sold as Glucantime in France, and Glucantim in Italy. It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.
See also
[edit | edit source]References
[edit | edit source]- ↑ PMID 9455509 (PMID 9455509)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ Aventis press release, 15 April 2005. Template:De icon
Licensed under CC BY-SA 3.0 | Source: https://www.wikidoc.org/index.php/Meglumine_antimonate4 views | ↧ Download this article as ZWI file
EncycloReader
is supported by the 
KSF